Patient disposition. †A patient could have multiple reasons for screening failure or exclusion from efficacy analysis. ‡These patients comprised the safety set. §Efficacy was assessed using the per-protocol analysis set. ||Because of worsening of cardiac T2* in 3 deferasirox patients and 3 DFO patients, LVEF decreased <50% in 1 DFO patient and cardiomegaly in 1 deferasirox patient.